These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 34177879)
1. Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients. Wei L; Shang Y; Liu X; Li X; Chen G; Liang S; Zou Z; Ding T; Hong Z; Wu M; Xia J Front Immunol; 2021; 12():580989. PubMed ID: 34177879 [TBL] [Abstract][Full Text] [Related]
2. A retrospective comparison of drugs against COVID-19. Tan J; Yuan Y; Xu C; Song C; Liu D; Ma D; Gao Q Virus Res; 2021 Mar; 294():198262. PubMed ID: 33333102 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China. Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B Front Immunol; 2021; 12():614436. PubMed ID: 33790892 [TBL] [Abstract][Full Text] [Related]
4. Clinical and antibody characteristics reveal diverse signatures of severe and non-severe SARS-CoV-2 patients. Wang H; Yan D; Li Y; Gong Y; Mai Y; Li B; Zhu X; Wan X; Xie L; Jiang H; Zhang M; Sun M; Yao Y; Zhu Y Infect Dis Poverty; 2022 Feb; 11(1):15. PubMed ID: 35109926 [TBL] [Abstract][Full Text] [Related]
5. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
6. Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients. Liao B; Chen Z; Zheng P; Li L; Zhuo J; Li F; Li S; Chen D; Wen C; Cai W; Wu S; Tang Y; Duan L; Wei P; Chen F; Yuan J; Yang J; Feng J; Zhao J; Zhao J; Sun B; Zhu A; Li Y; Tang X Front Immunol; 2021; 12():724763. PubMed ID: 34489978 [TBL] [Abstract][Full Text] [Related]
7. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152 [TBL] [Abstract][Full Text] [Related]
8. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK Front Immunol; 2021; 12():793953. PubMed ID: 34899762 [TBL] [Abstract][Full Text] [Related]
9. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. Nguyen-Contant P; Embong AK; Kanagaiah P; Chaves FA; Yang H; Branche AR; Topham DJ; Sangster MY mBio; 2020 Sep; 11(5):. PubMed ID: 32978311 [TBL] [Abstract][Full Text] [Related]
10. Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients. Maghsood F; Hassani D; Salimi V; Kardar GA; Khoshnoodi J; Ghaderi A; Raeeskarami SR; Rostamian A; Seyyedsalehi MS; Ahmadi Fesharaki R; Jeddi-Tehrani M; Zarnani AH; Amiri MM; Shokri F Viral Immunol; 2021 Dec; 34(10):708-713. PubMed ID: 34534012 [TBL] [Abstract][Full Text] [Related]
14. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S Front Immunol; 2021; 12():793191. PubMed ID: 34975897 [TBL] [Abstract][Full Text] [Related]
15. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects. Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828 [TBL] [Abstract][Full Text] [Related]
16. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. Zhu Z; Lu Z; Xu T; Chen C; Yang G; Zha T; Lu J; Xue Y J Infect; 2020 Jul; 81(1):e21-e23. PubMed ID: 32283143 [TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects. Achiron A; Gurevich M; Falb R; Dreyer-Alster S; Sonis P; Mandel M Clin Microbiol Infect; 2021 Sep; 27(9):1349.e1-1349.e6. PubMed ID: 33975009 [TBL] [Abstract][Full Text] [Related]
18. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390 [TBL] [Abstract][Full Text] [Related]
19. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. Secchi M; Bazzigaluppi E; Brigatti C; Marzinotto I; Tresoldi C; Rovere-Querini P; Poli A; Castagna A; Scarlatti G; Zangrillo A; Ciceri F; Piemonti L; Lampasona V J Clin Invest; 2020 Dec; 130(12):6366-6378. PubMed ID: 32991329 [TBL] [Abstract][Full Text] [Related]
20. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]